Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Zoledronic Acid Injection, USP in the United States as a therapeutic generic equivalent for Zometa® as approved by the U.S. Food and Drug Administration. Zoledronic Acid Injection, USP is indicated for the treatment of hypercalcemia of malignancy and for the treatment of multiple myeloma and bone metastases of solid tumors, in conjunction with standard antineoplastic therapy.
Avenacy’s Zoledronic Acid Injection, USP is available as a 4 mg/5 mL (0.8 mg per mL) single-dose vial. In line with Avenacy’s mission to champion patient safety and streamline patient care, Zoledronic Acid Injection, USP will feature the Company’s highly differentiated packaging and labeling to support accurate medication selection.
Avenacy will begin shipping Zoledronic Acid Injection, USP to wholesale partners this week. The Company is supported by a global network of development and contract manufacturing partners that have undergone successful FDA inspections based on cGMP-standards.
Zoledronic Acid Injection, USP had U.S. sales of approximately $11.4 million for the twelve months ending in September 2024.
